

## Reig Jofre and Ojer Pharma obtain the first European authorization for the commercialization of their innovative antibiotic Impetine® Gel

- Impetine® is an innovative mupirocin antibiotic bioadhesive gel used for the treatment of dermatological infections such as impetigo, folliculitis and furunculosis
- First commercialization authorization obtained for the Portuguese market and authorization processes initiated in the rest of the European Union, in addition to Mexico and Canada. Advanced negotiations in progress in the United States, Asia, LATAM and the MENA area

**Barcelona (Spain), November 12, 2019**, Pharmaceutical companies Reig Jofre and Ojer Pharma have recently received market authorization from the Portuguese Medicines Agency (Infarmed) for Impetine® Gel, an innovative mupirocin antibiotic bioadhesive gel used for the treatment of primary dermatological infections such as impetigo, folliculitis and furunculosis, and secondary infections such as overinfected dermatoses of the skin.

The product, which has been developed by both companies in collaboration with various Spanish R&D centres and universities and patented in the main international markets, has successfully passed the preclinical and clinical development phases and has demonstrated an optimized efficacy and safety profile with respect to the reference product, making it the first topical mupirocin antibiotic on the market, presented in an innovative transparent and bioadhesive gel in the form of a sustained-release matrix.

Impetine® is a clear example of how incremental innovation provides added value to patients, health professionals and the national health system, by offering a better antibiotic treatment with a better dosage and formulation that facilitates greater treatment adherence and thus contributes to the correct use of antibiotics.

Simultaneous to this first process, the authorization procedure has been initiated in the rest of the countries of the European Union, as well as in Mexico and in Canada, with a favourable response having been obtained to the consultation made before the Canadian Agency.



In recent years, the consortium has reached different license agreements for the commercial exploitation of Impetine® with leading international pharmaceutical groups (Spain, Portugal, Italy, Belgium, Germany, Greece, Hungary, Mexico and Canada).

Additionally, important options are being negotiated in the United States, Asia, LATAM (Latin America) and the MENA area (Middle East and North Africa), where both companies hold the corresponding industrial property rights.

The commercialization of Impetine® Gel is expected to begin in the first quarter of 2020 in Portugal, and throughout 2021 in Spain, Italy, Greece, Hungary, Canada and Mexico. By 2025, Impetine® is expected to be the most prescribed topical antibiotic in Spain, with more than 2 million units sold.

According to the Infectious Diseases Society of America (IDSA), the prevalence of such dermatological infections ranges from between 7% to 15% of the world population (between 500 and 1,000 million cases / year), one of the highest incidences recorded for such conditions. Specifically, impetigo, a condition which is highly prevalent in children, reaches 200 million cases a year worldwide; an average prevalence of 14.5% in Europe, with Italy and Greece at the head, while Spain is in the middle range with a prevalence of 17.5% and a record of around 8 million cases a year.

In the words of Carlos González, Director of Laboratorios Ojer Pharma, *"this important technical milestone simply validates the company's product development strategy, which will allow us to extend the authorization to other countries of interest and respond to the commercialization license agreements already reached."*

For his part, the CEO of Reig Jofre, Ignasi Biosca, points out that *"Impetine is an example of our commitment to innovation through the creation of successful strategic alliances with intensive R&D companies that result in access to new formulations providing an added value that is appreciated both by patients and by the market."*

### **About Impetine®**

Impetine® Gel is an innovative transparent and bioadhesive formulation that acts as a sustained-release matrix film that facilitates the controlled release of the active substance mupirocin, optimizing safety and efficacy by reducing the number of applications necessary. Additionally, the film isolates the treatment area, preventing the spread of the infection and eliminating the need for dressings, thus avoiding changes in skin permeability and reducing local side effects.



### **About Ojer Pharma**

Laboratorios Ojer Pharma is a pharmaceutical company, a spin-off from the University of Navarra, founded in 2005 by its founding partner (Carlos González Ojer) under the umbrella of the Centre for Research in Applied Pharmacobiology (CIFA) and the University of Navarra Foundation (FUNA). Ojer Pharma directs all its efforts to the development of vehiculization products and technologies that address dermatological pathologies (human and veterinary) from a multifunctional perspective (causes and symptoms) and which optimize the safety and efficacy profiles of conventional dermatological treatments. The company has received technical and financial support from leading specialized biotechnology partners, such as the University of Navarra (UN), the Navarra Development Society (SODENA) Clave Mayor, Inveready and Easo Ventures, as well as leading investors present in the sector, such as Antonio Parente, with the aim of becoming a reference within the dermatological sector. For more information about Ojer Pharma, please visit [www.ojerpharma.com](http://www.ojerpharma.com)

### **About Reig Jofre**

Founded in 1929 in Barcelona, Reig Jofre is a pharmaceutical company listed on the Spanish Stock Exchange's continuous market and dedicated to the research, development, manufacture and marketing of pharmaceutical products and nutritional supplements. Reig Jofre structures its product development activity in three business areas: pharmaceutical technologies specialized in the development and manufacture of sterile and lyophilized injectable pharmaceutical products, as well as antibiotics derived from penicillin. Specialty products focused on the research, development, manufacture and commercialization of specialties in, above all, the areas of (i) skin, hair and nail health, (ii) joint health and pain, and (iii) women's health, And Consumer Healthcare, of which special mention may be made of the line of nutritional supplements, which are marketed under the brand Forté Pharma mostly in France, Belgium, Spain and Portugal, as well as other OTC products. Reig Jofre has more than 1000 employees, 4 development and production centres in Europe (2 in Toledo, 1 in Barcelona and 1 in Sweden), direct sales in 7 countries and more than 130 business partners in 70 countries around the world. The company closed 2018 with a turnover of 181 million euros. Reig Jofre is quoted on the Spanish stock exchange's continuous market under the ticker RJF. Share capital: 76,062,457 shares

### **For more information**

---

Inma Santa-Pau - Head of Communication and Investor Relations  
Tel. (+34) 935 450 078 - [inma.santapau@reigjofre.com](mailto:inma.santapau@reigjofre.com)  
[www.reigjofre.com](http://www.reigjofre.com)